BCAX

Bicara Therapeutics Inc. is a biotechnology company operating in the healthcare sector. The company has a market capitalization of $882.54 million and employs 55 individuals. Bicara Therapeutics Inc.'s scale is notable within its industry. Financially, the company's profitability metrics are negative across the board. Gross margin, operating margin, and profit margin are all at 0.0%. The company's returns on equity and assets are also negative, standing at -26.6% and -18.6%, respectively. On a balance sheet perspective, the company has a debt-to-equity ratio of 0.49 and a current ratio of 14.14. Additionally, Bicara Therapeutics Inc. has $290.17 million in cash and $1.98 million in debt. Valuation metrics for Bicara Therapeutics Inc. show a P/E ratio (TTM) of 3.05 and a forward P/E of -5.46. The company's price to book is 2.18, and its EV/EBITDA is -4.32. These numbers provide context for the company's valuation within its industry and sector.